Fintel reports that on November 4, 2025, Citizens maintained coverage of Vertex (NasdaqGM:VERX) with a Market Outperform ...

Fintel reports that on November 4, 2025, Stifel maintained coverage of Vertex (NasdaqGM:VERX) with a Hold recommendation.

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

Vertex Pharmaceuticals (VRTX) swung to profitability as the company left behind five years of annual earnings declines ...

Vertex (VERX) remains unprofitable but is narrowing its losses at an average rate of 16.4% per year over the past five years. Looking ahead, the company’s annual revenue is expected to grow by 12.4% ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear ...

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

For the quarter ended September 30, Vertex Pharmaceuticals reported adjusted earnings of $4.80 per share, marking an increase from $4.38 in the same quarter last year. This positive performance not ...

In the competitive landscape of pharmaceuticals, Vertex Pharmaceuticals has recently encountered hurdles with its latest offerings, Journavx and Casgevy, which have not met Wall Street's expectations.

Vertex (NASDAQ: VERX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table below ...

The stock's fall snapped a three-day winning streak.